探索GLP-1受体激动剂的多方面的作用;一个全面的审查
Bisma Fatima Hammad1, Nimrah Zafar2, Muneeb Ullah3
1Hammad Department of Medicine, Liaquat National Hospital and Medical College, Karachi, Pakistan.
Frontiers in clinical diabetes and healthcare
|July 25, 2025
概括
类似葡萄糖类-1 (GLP-1) 受体激动剂在2型糖尿病之外显示出有前途,影响体重,心脏健康和神经保护. 需要进一步的研究来证实长期的安全性和成本效益,以获得更广泛的患者接入.
科学领域:
- 药理学和内分泌学 药理学和内分泌学
- 代谢疾病 代谢疾病
- 心血管医学 心血管医学
背景情况:
- 类似葡萄糖-1受体激动剂 (GLP-1RAs) 模仿内源GLP-1,在2型糖尿病管理中显示出有效性.
- GLP-1受体存在于多个器官,包括大脑,心脏和胰腺,表明不同的生理作用.
研究的目的:
- 审查GLP-1RAs在2型糖尿病之外的扩展治疗应用.
- 突出显著的研究表明GLP-1RAs对各种身体器官的生理作用.
- 确定未来研究领域,包括长期的安全性和成本效益.
主要方法:
- 关于GLP-1受体激动剂作用的最近研究的文献综述.
- 强调重要的和值得注意的研究成果.
- 对不同生理系统的治疗影响的分析.
主要成果:
- GLP-1RAs有助于血糖调节,体重管理,心血管健康和神经保护.
- 还观察到对肌肉骨健康的积极影响.
- 该审查强调了GLP-1RA在各种疾病背景中的扩大作用.
结论:
- GLP-1RAs为广泛的疾病提供了显著的治疗潜力.
- 进一步的综合性研究对于确定长期安全性和优化患者治疗结果至关重要.
- 对GLP-1RAs的成本效益的研究对于全球可访问性至关重要.
相关概念视频
Glucagon-like Receptor Agonists
420
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
420
Oral Hypoglycemic Agents: Glinides
263
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
263
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
263
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
263
Dipeptidyl Peptidase 4 Inhibitors
261
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
261
Oral Hypoglycemic Agents: Biguanides and Glitazones
304
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
304
G Protein-coupled Receptors
13.5K
G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
13.5K


